Skip to main content

Table 2 Primary and secondary outcomes

From: High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study

Outcomes Standard oxygen therapy HFNO unadjusted IPTW
OR [IC95%] p OR [IC95%] p
IMV—no (%) 46/62 (74%) 39/76 (51%) 0.37 [0.18–0.76] 0.007 0.31 [0.14–0.66] 0.002
Death at D28—no (%) 15/62 (24%) 9/76 (12%) 0.42 [0.17–1.04] 0.061 0.52 [0.2–1.34] 0.17
Death at D60—no (%) 16/62 (26%) 12/76 (16%) 0.54 [0.23–1.25] 0.15 0.75 [0.32–1.8] 0.52
Ventilator free days, days (IQR) 10 (0–27) 21(5–28) 0.005
Mean length of stay, days (IQR) 12.5 (4–24) 11 (5–20) −0.04 [−0.35 to 0.27] 0.78 −0.23 [−0.54 to 0.08] 0.14
  1. IMV invasive mechanical ventilation, HFNO high flow nasal canula, IPTW inverse probability of treatment weighting, IQR interquartile